Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

From Pharma Insider To Payer: Witty To Lead United's Optum

Executive Summary

Former GSK CEO Witty stood out among big pharma chief execs for his pessimistic outlook on US drug pricing, which shaped his diversification strategy at GSK. His experience as a pharma insider makes him an interesting choice to lead United's PBM and health services arm.

You may also be interested in...



Coronavirus Update: Remedesivir China Trials Halted, Witty To Spearhead WHO's Vaccines Efforts

Plus: Korean firms working on repurposed drug which showed far higher efficacy than remdesivir and chloroquine in pre-clinical tests

Appointments: Rice Goes To CVS, A New CFO At J&J And Changes at Merck & Co, Alder, Hansa, OncoMed, Modus Therapeutics, Astellas Americas And Others

This week's new appointments include the move by the second former big pharma executive to a PBM in the space of a week, plus a new CFO at Johnson & Johnson, and new CEOs at Alder BioPharmaceuticals, OncoMed and Hansa Medical. Other hires were announced by Astellas Americas, Merck & Co, Valbiotis, Bicycle Therapeutics, Sorrento Therapeutics, Gritstone Oncology and Oxford BioMedica. 

Praluent Pricing: Collaboration With ICER Sets A New Standard

Sanofi/Regeneron reveal plans to lower price of PCSK9 blocker Praluent to match ICER's updated recommendation, following assessment based on new outcomes data. Decision sparks debate across industry and raises questions about setting precedent on pricing for the future.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel